LatchBio's antibody discovery benchmark: Opus and Gemini lead, OpenAI models underperform
kenbwork · x · 2026-09-03
LatchBio introduces an Antibody Discovery Benchmark testing whether AI agents can make scientific decisions across stages of therapeutic antibody discovery.
- 100 evaluations across 10 areas drawn from concrete drug programs: target and modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical candidate de-risking.
- Discovery is multiparameter and context-dependent: affinity must be weighed against specificity, stability, solubility, expression, and biological activity, and every measurement interpreted within its experimental system.
Early results: Claude Opus and Gemini do well; OpenAI models do poorly overall — a surprising gap.
Related event: LatchBio Releases Antibody Discovery Benchmark for AI Agents(5 posts)→
More from Research
- Opus-assisted open design: a $31k low-field head MRI sketched in hours — DreamFly_13 · 2026-10-18
- semiconductor.diy: open-source guides to make real chips in a garden shed — jwt0625 · 2026-10-18
- Work in progress: geometric structure of GPG projections as Markov chain coarsening — michaelchchoi · 2026-10-18
- Backprop-free pretraining gets 2.3x speedup as Noise method crushes Dust record on 8 GPUs — inductionheads · 2026-10-18
- q3dviewer: open-source Qt+OpenGL tool for painter-like point cloud editing — 4310sy · 2026-10-18
- Smarter Every Day's Destin to defend PhD dissertation on impact fusion — CatAstro_Piyush · 2026-10-18